Compare AstraZeneca plc (AZN) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Philip Morris International Inc. — how do they compare? AstraZeneca plc trades at $166.95 (market cap $253.13B), while Philip Morris International Inc. trades at $176.88 (market cap $274.23B). The key difference: AstraZeneca plc and Philip Morris International Inc. are close in size by market cap, and Philip Morris International Inc. pays the higher dividend (3.34%). Which is the better fit depends on your goals.
| AZN | PM | |
|---|---|---|
Market Cap | $253.13B | $274.23B |
Sector | Health | Consumer Staples |
52-Week High | $209.48 | $191.86 |
52-Week Low | $137.44 | $144.33 |
Enterprise Value | $279.37B | $320.73B |
Dividend Yield | 1.92% | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Philip Morris International (PM) trades at $175.95, down 3.12% on the day, amid a recent profit forecast revision. The stock shows a bullish technical signal with key support at $175 and resistance at $183. Fundamentally, the company reported strong 2025 results with $40.65B revenue and $11.35B net income, though a $500M impairment charge and cost pressures prompted a lowered 2026 outlook. Analyst sentiment remains positive with a $194 consensus price target and 68% buy ratings.
The outlook is cautiously optimistic; earnings growth and the IQOS brand strength offer upside, but regulatory risks and illicit market pressures pose challenges. The current price presents a potential entry point below the analyst target, though investors must weigh margin pressures from energy costs and currency swings noted in recent company guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
